Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

JW (Cayman) Therapeutics Co. Ltd. (2126) Price & Analysis

2126 Stock Chart & Stats

HK$2.22-HK$0.01(-0.45%)
At close: 4:00 PM EDT
HKD 1.5HKD 2HKD 2.5HKD 33 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
HKD 2.15 - HKD 2.28
52-Week Range
HKD 1.40 - HKD 4.18
Previous Close
HKD 2.23
Volume
104.00K
Average Volume (3M)
1.75M
Market Cap
HKD 925.48M
Enterprise Value
HKD 507.99M
Total Cash (Recent Filing)
HKD 392.02M
Total Debt (Recent Filing)
HKD 254.85M
Price to Earnings (P/E)
―
Beta
1.65
Next Earnings
Apr 01, 2027
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Gross-margin Improvement

The sharp 2025 revenue rebound, alongside improved gross margin, indicates stronger commercialization and better economics for the company’s therapy portfolio. If sustained, this combination can expand operating leverage, support reinvestment in clinical programs, and improve the path toward eventual profitability.

Reduced Operating Cash Burn

The substantial reduction in operating cash burn suggests improved cost control and/or working-capital dynamics. Although cash generation remains negative, a smaller recurring outflow preserves financial flexibility for longer and gives management more time to scale revenue and progress toward break-even.

Manageable Debt Leverage

Debt does not currently appear to be the primary balance-sheet constraint, as leverage remains below one times equity. This provides more flexibility than a highly levered structure to fund development and commercialization, while reducing the immediate burden of debt-related financial risk.

Bears Say

Deep And Persistent Unprofitability

Despite stronger revenue and narrower losses, the company remains far from operating break-even. A deeply negative net margin means commercial growth is not yet translating into sustainable earnings, leaving profitability dependent on further scale, cost improvement, or successful product expansion.

Ongoing Negative Free Cash Flow

Persistent negative free cash flow limits the company’s ability to finance research, clinical development, and commercialization internally. Until cash generation turns positive, JW Therapeutics may need continued access to external capital, which can constrain strategic flexibility and increase funding risk.

Equity Erosion From Accumulated Losses

Ongoing losses have weakened the capital base over time, as reflected in material equity erosion and very negative returns on equity. Continued deterioration could reduce financial resilience and make future investment, funding, or expansion decisions more dependent on raising additional capital.

JW (Cayman) Therapeutics Co. Ltd. News

2126 FAQ

What was JW (Cayman) Therapeutics Co. Ltd.’s price range in the past 12 months?
JW (Cayman) Therapeutics Co. Ltd. lowest stock price was HK$1.40 and its highest was HK$4.18 in the past 12 months.
What is JW (Cayman) Therapeutics Co. Ltd.’s market cap?
JW (Cayman) Therapeutics Co. Ltd.’s market cap is HK$925.48M.
When is JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were JW (Cayman) Therapeutics Co. Ltd.’s earnings last quarter?
JW (Cayman) Therapeutics Co. Ltd. released its earnings results on Aug 27, 2026. The company reported -HK$0.14 earnings per share for the quarter.
Is JW (Cayman) Therapeutics Co. Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does JW (Cayman) Therapeutics Co. Ltd. pay dividends?
JW (Cayman) Therapeutics Co. Ltd. does not currently pay dividends.
What is JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate?
JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JW (Cayman) Therapeutics Co. Ltd. have?
JW (Cayman) Therapeutics Co. Ltd. has 416,883,360 shares outstanding.
What happened to JW (Cayman) Therapeutics Co. Ltd.’s price movement after its last earnings report?
JW (Cayman) Therapeutics Co. Ltd. reported an EPS of -HK$0.14 in its last earnings report. Following the earnings report the stock price went up 4.651%.
Which hedge fund is a major shareholder of JW (Cayman) Therapeutics Co. Ltd.?
Currently, no hedge funds are holding shares in HK:2126
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology